EORTC presentations at CTOS
7 Nov 2016
EORTC will present four abstracts at the Connective Tissue Oncology Society (CTOS) 21st Annual Meeting, which will take place from 9 to 12 Novembre 2016 in Lisbon, Portugal.
Oral abstract session
Second Safety Analysis of A Phase III Randomized Study of Pre-Operative Radiotherapy (RT) Plus Surgery Versus Surgery Alone for Patients With Retro Peritoneal Sarcoma (RPS) – EORTC 62092-22092- STRASS
Oral Session STS: Retroperitoneal STS; Thu 10.11.2016 – 5:10 PM to 5:55 PM
Authors: Sylvie Bonvalot, Rick L. M. Haas, Saskia Litière, Cecile Le Pechoux, Dirk C Strauss, Carol Jane Swallow, Piotr Rutkowski, Chandrajit P. Raut, Michela Lia, Sandrine Marréaud, Alessandro Gronchi
Poster sessions
Prognosis of Patients Receiving First Line Chemotherapy for Advanced Soft Tissue Sarcomas with Locally Advanced Vs Distant Metastasis Vs Both: An EORTC-STBSG Database Analysis
Poster Session 2: STS 095; Friday 11.11.2016 – 6:15 PM to 7:00 PM
Authors: A.J. Verschoor, S. Litière, S. Marréaud, I. Judson, M. Toulmonde, E. Wardelmann, W. van der Graaf, A. Le Cesne, A. Gronchi, H. Gelderblom
Prospective Validation Of A Molecular Signature Predictive Of Response To Trabectedin In Soft-Tissue Sarcomas Within EORTC 62091 Trial
Poster Session 2: STS 096; Friday 11.11.2016 – 6:15 PM to 7:00 PM
Authors: Italiano A, Touati N, Litière S, Butrynski JE, Penel N, Blay JY, Isambert N, Milhem M, Kerst JM, Reyners AKL, Marréaud S, Collin F, Van der Graaf WT, Gelderblom AJ, Gronchi A
Impact on outcome of concomitant administration of gastric acid suppression (GAS) therapy and pazopanib in soft tissue sarcoma (STS) patients treated within EORTC 62043/62072 trials.
Poster Session 2: STS 113; Friday 11.11.2016 — 6:15 PM to 7:00 PM
Authors: Mir O, Touati N, Lia M, Litière S, Le Cesne A, Sleijfer S, Leahy M, Young R, Mathijssen R, Van Erp NP, Gelderblom AJ, Van der Graaf WT, Gronchi A
Pazopanib In Advanced Vascular Sarcomas: An EORTC Soft Tissue And Bone Sarcoma Group Retrospective Analysis
Poster Session 2: STS 123; Friday 11.11.2016 — 6:15 PM to 7:00 PM
Authors: Kollár A, Jones RL, Stacchiotti S, Gelderblom H, Guida M, Boccone P, Steeghs N, Safwat A, Katz D, Duffaud F, Sleijfer S, van der Graaf WT, Touati N, Litière S, Marréaud S, Gronchi A, Kasper B
Related News
EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma
11 Dec 2024
Minister F. Vandenbroucke visits EORTC Headquarters to strengthen collaborative efforts in clinical cancer research
21 Nov 2024
IMMUcan has completed patient enrolment
12 Nov 2024
EORTC SPRINT clinical cancer study receives support from Rising Tide Foundation to reduce the burden for patients
5 Nov 2024
Pink October at EORTC: Over 60 years of impactful breast cancer research
29 Oct 2024
Spotlight on ENA 2024 News
25 Oct 2024
Do regulations and policies undermine the social value of independent academic research?
25 Oct 2024
EORTC Quality of Life Group’s participation to ISOQOL 2024
10 Oct 2024
New Insights into Glioblastoma Treatment for Older Adults Patients
8 Oct 2024
TOPGEAR trial results show no significant benefit of preoperative chemoradiotherapy on long term survival
24 Sep 2024